Yes, Sirna: Merck Inks $1.1 Bil. Deal For RNAi Firm
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck continues acquisition spurt with purchase of San Francisco biotech.
You may also be interested in...
Merck Passes Huntington’s RNAi Program To Targeted Genetics
Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.
Merck Passes Huntington’s RNAi Program To Targeted Genetics
Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.
GSK Partners With Santaris On RNA Antagonists For Viral Disease
$700 million deal gives GlaxoSmithKline options on up to four different viral disease programs; deal marks Santaris’ expansion into virology, chief exec McCullah tells “The Pink Sheet” DAILY.